The "Triple Agonist" Everyone's Asking About — What It Actually Does, and When You Might Be Able to Get It
A patient sent me a screenshot last week. A headline claiming a new weight loss drug beats Ozempic and Zepbound combined, with a number attached that looked almost too high to be real.
She wanted to know: is this real, and should I wait for it instead of starting what my doctor already prescribed?
Good question. Let's talk about retatrutide — what it actually is, what the data actually shows, and the honest answer on when you'll be able to get it.
WHAT MAKES RETATRUTIDE DIFFERENT: THE TRIPLE ACTION
You're already familiar with how GLP-1 medications work from earlier in this series. Semaglutide (Ozempic, Wegovy) targets one receptor: GLP-1. Tirzepatide (Mounjaro, Zepbound) targets two: GLP-1 and GIP. That dual action is part of why tirzepatide tends to outperform semaglutide for weight loss.
Retatrutide goes one step further. It's a triple hormone receptor agonist, activating three separate receptors at once: GLP-1, GIP, and glucagon.
That third target, glucagon, is the genuinely new piece. Glucagon is typically known for raising blood sugar, the opposite job of insulin. But at the doses used in retatrutide, activating the glucagon receptor appears to increase energy expenditure and support fat breakdown, working alongside the appetite suppression and blood sugar regulation that GLP-1 and GIP already provide. Three mechanisms, three separate angles on the same underlying biology, in a single weekly injection.
IS IT MORE EFFECTIVE THAN TIRZEPATIDE? THE DATA, HONESTLY
Yes, based on everything published so far, and the gap isn't small.
In the Phase 3 TRIUMPH-1 trial, participants on the highest dose lost an average of 28.3% of body weight at 80 weeks, with nearly half of participants losing 30% or more, a level of weight loss historically associated with bariatric surgery. A separate Phase 3 trial, TRIUMPH-4, found participants lost an average of 28.7% of body weight, about 71 pounds, over 68 weeks.
For comparison: semaglutide (Wegovy) produced roughly 15 to 17% weight loss in its pivotal trials. Tirzepatide (Zepbound) landed around 20 to 21%. Retatrutide's 24 to 28% range, depending on the trial and dose, is the highest figure recorded for any injectable obesity medication in a controlled trial to date.
It isn't only about weight loss. In a Phase 3 trial specifically in people with type 2 diabetes, retatrutide produced superior A1c reduction and weight loss compared to placebo, with 82% of participants reaching an A1c of 6.5% or lower, a level considered near-normal glycemic control. Earlier Phase 2 data also showed up to an 82% reduction in liver fat, a striking finding for a condition, MASH, that currently has no approved pharmacological treatment in the United States.
WHAT ABOUT THE SIDE EFFECTS OF TRIPLE ACTION?
This is the part worth understanding clearly before getting excited about the headline numbers.
The gastrointestinal side effects look similar to what you'd expect from any GLP-1 class medication: nausea, vomiting, diarrhea, and constipation, generally manageable with the same slow dose titration strategy used for semaglutide and tirzepatide. Roughly 10% of trial participants discontinued due to side effects, a rate comparable to both tirzepatide and semaglutide, not meaningfully worse despite the added mechanism.
There is one side effect that's genuinely new, and it's specific to the glucagon component: dysesthesia, an unusual skin sensation described as tingling, tenderness, or heightened sensitivity to touch. In trial data, approximately 21% of patients on the highest dose reported this. It was generally described as mild, but it's a side effect we haven't seen with dual or single-agonist GLP-1 medications, and it's worth knowing about specifically because of the third mechanism doing the added work.
The honest clinical summary: more powerful weight loss, a side effect profile that looks largely familiar, plus one new and unique sensation to watch for that comes specifically from the glucagon activity.
WHEN CAN YOU ACTUALLY GET IT?
Here's the part I want to be very direct about, because there's a lot of misleading content online suggesting retatrutide is already accessible.
It is not. Retatrutide is not FDA approved. It is currently available only within Eli Lilly's clinical trial programs, not at any pharmacy, and not through any legitimate prescription pathway in the United States.
Several Phase 3 trials have now reported strong results, and Eli Lilly has additional Phase 3 trials expected to complete through 2026. Based on the standard FDA timeline, a New Drug Application submission is expected sometime in late 2026, followed by a 6 to 10 month review period. The realistic projection right now is FDA approval sometime in late 2027, with retail availability likely following in early 2028.
One important warning, the same one I'd give about any unapproved medication: the FDA has specifically warned against obtaining retatrutide through compounding pharmacies or online sellers claiming early access. A medication that hasn't completed the approval process hasn't been fully evaluated for safety, and counterfeit or mislabeled products are a real risk in this space. If you see retatrutide being sold or offered right now, that is not a legitimate or safe source, regardless of how it's marketed.
WHAT THIS MEANS FOR YOU TODAY
If you're currently on a GLP-1 medication, or starting one soon, the honest answer is: don't wait for retatrutide. Semaglutide and tirzepatide are approved, available, and backed by years of real-world outcome data, including the cardiovascular and metabolic benefits we covered earlier in this series. Waiting one to two years for a medication that may offer a few additional percentage points of weight loss means delaying treatment you could be benefiting from right now.
What retatrutide does represent is genuinely exciting: a glimpse at where this entire medication class is heading. Multiple mechanisms working together, addressing more of the underlying metabolic biology at once, rather than a single pathway. It's a sign that the tools available for metabolic health are going to keep getting more precise, not that what's currently available isn't already effective.
And the nutritional principles underneath all of it stay exactly the same, regardless of which medication eventually gets approved. Protein to protect muscle. Fiber to support your gut and satiety. A Mediterranean-style foundation to manage inflammation and support the metabolic improvements the medication is working toward. The mechanism changes. The nutrition foundation underneath it doesn't.
Want to build that foundation now, regardless of which medication you're on or considering down the road? That's exactly what I do. Book a consultation here.
References: Eli Lilly and Company, TRIUMPH-1 and TRIUMPH-4 Phase 3 trial results (2025-2026). Eli Lilly and Company, TRANSCEND-T2D-1 Phase 3 trial results (2026). Jastreboff AM et al., Triple Agonism Based Therapies for Obesity, PMC (2026). Efficacy and safety of retatrutide: a systematic review and meta-analysis of randomized controlled trials, PMC (2026). GoodRx, Retatrutide for Weight Loss: Availability, Dosage, and More (2026). Drugs.com, Retatrutide: What is it and is it FDA approved? (2026).
